Page last updated: 2024-10-24

epigenetic programming of gene expression

Definition

Target type: biologicalprocess

A epigenetic process that happens during embryonic development that modulates gene expression potential at later stages of development of the organism, including the adult. Epigenetic regulation takes place via chromatin remodeling either by modifying higher order chromatin fiber structure, nucleosomal histones, or cytosine DNA methylation. [GOC:go_curators, PMID:12138111, PMID:22868271]

Epigenetic programming of gene expression is a dynamic and intricate process that orchestrates the accessibility and activity of genes without altering the underlying DNA sequence. It involves modifications to chromatin, the complex of DNA and proteins that packages the genome within the nucleus of a cell. These modifications can be inherited through cell division and influence diverse cellular functions, including development, differentiation, and disease susceptibility.

Key players in this process include:

1. **DNA methylation:** The addition of a methyl group to cytosine bases in DNA, often at CpG dinucleotides. Methylation patterns can be established during development and maintained throughout life. Generally, methylation silences gene expression by hindering the binding of transcription factors and recruiting proteins that compact chromatin.

2. **Histone modifications:** Histone proteins act as spools around which DNA is wrapped. Modifications to histone tails, such as acetylation, methylation, phosphorylation, and ubiquitination, can alter the accessibility of DNA to transcription factors. For instance, histone acetylation typically promotes gene expression by loosening chromatin structure, while histone methylation can either activate or repress gene expression depending on the specific amino acid residue and the degree of methylation.

3. **Non-coding RNAs:** A diverse class of RNA molecules that do not encode proteins but play critical roles in gene regulation. Some non-coding RNAs, such as microRNAs (miRNAs), can silence gene expression by targeting messenger RNA (mRNA) for degradation or translational repression. Others, like long non-coding RNAs (lncRNAs), can act as scaffolds for protein complexes that modulate chromatin structure and gene expression.

4. **Chromatin remodeling complexes:** These protein complexes can reposition nucleosomes, the basic units of chromatin, to expose or conceal specific DNA sequences. Their activities are often regulated by signals from the cellular environment or by other epigenetic modifications.

These modifications, acting in concert, establish a complex and dynamic epigenetic landscape that influences gene expression profiles. During development, epigenetic programming helps establish cell fate by specifying which genes are active or inactive in different cell types. This process is essential for the proper development and function of tissues and organs.

Epigenetic programming is also involved in the adaptation of organisms to environmental challenges and in disease pathogenesis. For example, exposure to environmental toxins can lead to epigenetic modifications that contribute to cancer development. Conversely, lifestyle interventions, such as exercise and diet, can influence epigenetic patterns and potentially promote health and longevity.

The field of epigenetics is rapidly evolving, and new discoveries are constantly shedding light on the intricate mechanisms and far-reaching implications of epigenetic programming. Understanding this process is crucial for developing strategies to treat diseases, prevent adverse health outcomes, and optimize human health.'
"

Proteins (1)

ProteinDefinitionTaxonomy
DNA (cytosine-5)-methyltransferase 1A DNA (cytosine-5)-methyltransferase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P26358]Homo sapiens (human)

Compounds (21)

CompoundDefinitionClassesRoles
procainamideprocainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.

Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
benzamidesanti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker
vorinostatvorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
dicarboxylic acid diamide;
hydroxamic acid
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
dichlonedichlone: structure
azacitidine5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.

Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
N-glycosyl-1,3,5-triazine;
nucleoside analogue
antineoplastic agent
epigallocatechin gallate(-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.

epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis)
flavans;
gallate ester;
polyphenol
antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
5,5'-methylenedisalicylic acid5,5'-methylenedisalicylic acid: inhibits attachment of ribosomes to microsomal membranes; RN given refers to parent cpd; structure in first source & Merck Index, 9th ed, #5934
s-tubercidinylhomocysteine
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene: structure given in first sourcemonoterpenoid;
organobromine compound;
organochlorine compound
algal metabolite;
antineoplastic agent;
marine metabolite
s-adenosyl-3-thiopropylamineS-adenosyl-3-thiopropylamine : A thioadenosine that is adenosine in which the hydroxy group at C-5' is replaced by a 3-aminopropyl group.

S-adenosyl-3-thiopropylamine: decarboxylated S-adenosylhomocysteine; RN given refers to parent cpd
organic sulfide;
primary amino compound;
thioadenosine
n(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid
nsc 401077NSC 401077: inhibits DNA methyltransferase DNMT1; structure in first source
s-adenosylhomocysteineS-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.

S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.
adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide
cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
decitabine2'-deoxyribonucleoside
rg108RG108: DNA methyltransferase inhibitor; structure in first sourceindolyl carboxylic acid
genistein7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
psammaplin apsammaplin A: isolated from marine sponges Poecillastra and Jaspis; structure in second source
sgi-1027SGI-1027: inhibits DNA methyltransferase 1; structure in first source
bix 01294piperidines
unc 0638UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first sourcequinazolines
gsk343GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).

GSK343: an EZH2 methyltransferase inhibitor
aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source